Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of -99.97% is 61% above its 5-year average of -259.54%, around the middle of its 5-year range (-4188.22%–5816.67%).
37.31% below its 12-month average of -72.81%.
Reported quarterly EBITDA margin; no daily interpolation. Q2 FY2026 (2026-06-30): -54.55%.
EBITDA MARGIN
-99.97%
EBITDA MARGIN AVG TTM
-72.81%
EBITDA MARGIN AVG 3Y
-174.32%
EBITDA MARGIN AVG 5Y
-259.54%
EBITDA MARGIN AVG 10Y
-388.43%
EBITDA MARGIN AVG 15Y
-363.92%
EBITDA MARGIN AVG 20Y
-326.10%
CURRENT VS TTM AVG
-37.31%
CURRENT VS 3Y AVG
+42.65%
CURRENT VS 5Y AVG
+61.48%
CURRENT VS 10Y AVG
+74.26%
CURRENT VS 15Y AVG
+72.53%
CURRENT VS 20Y AVG
+69.34%
TherapeuticsMD, Inc.
Market Cap
$23.38M
EBITDA Margin
-99.97%
TTM Avg
-72.81%
3Y Avg
-174.32%
5Y Avg
-259.54%
Market Cap
$24.13M
EBITDA Margin
-701.04%
TTM Avg
-599.88%
3Y Avg
-518.61%
5Y Avg
-381.18%
Market Cap
$24.44M
EBITDA Margin
-710238.40%
TTM Avg
-369696.29%
3Y Avg
-185511.92%
5Y Avg
-193923.76%
Market Cap
$24.60M
EBITDA Margin
-541.66%
TTM Avg
-507.83%
3Y Avg
-427.73%
5Y Avg
-407.72%
Market Cap
$22.00M
EBITDA Margin
-7.62%
TTM Avg
-5.66%
3Y Avg
-2.78%
5Y Avg
-31.67%
Market Cap
$25.22M
EBITDA Margin
-883.91%
TTM Avg
-2536.80%
3Y Avg
-2479.09%
5Y Avg
-2025.77%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| TherapeuticsMD, Inc. (TXMD) | $23.38M | -99.97% | -72.81% | -174.32% | -259.54% |
| Rein Therapeutics Inc. (RNTX)vs › | $23.06M | N/A | N/A | N/A | N/A |
| LeonaBio, Inc. (LONA)vs › | $22.68M | N/A | N/A | N/A | N/A |
| Kyntra Bio, Inc. (KYNB)vs › | $24.13M | -701.04% | -599.88% | -518.61% | -381.18% |
| Atossa Therapeutics, Inc. (ATOS)vs › | $24.44M | -710238.40% | -369696.29% | -185511.92% | -193923.76% |
| Modular Medical, Inc. (MODD)vs › | $22.25M | N/A | N/A | N/A | N/A |
| InspireMD, Inc. (NSPR)vs › | $24.60M | -541.66% | -507.83% | -427.73% | -407.72% |
| Aytu BioPharma, Inc. (AYTU)vs › | $22.00M | -7.62% | -5.66% | -2.78% | -31.67% |
| ABVC BioPharma, Inc. (ABVC)vs › | $25.22M | -883.91% | -2536.80% | -2479.09% | -2025.77% |
| NextCure, Inc. (NXTC)vs › | $20.53M | -168.97% | -358.59% | -358.59% | -358.59% |
Gross Margin
100.0%
EBITDA Margin
-100.0%
Operating Margin
-139.4%
Net Margin
-6.6%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-06-30 | -54.55% |
| 2026-03-31 | -86.88% |
| 2025-12-31 | -66.07% |
| 2025-09-30 | -93.62% |
| 2025-06-30 | -62.92% |
| 2025-03-31 | -279.39% |
| 2024-12-31 | -31.78% |
| 2024-09-30 | -189.76% |
| 2024-06-30 | -1114.96% |
| 2024-03-31 | -322.36% |
| 2023-12-31 | -194.02% |
| 2023-09-30 | 3101.89% |
| 2023-06-30 | -536.16% |
| 2023-03-31 | -634.62% |
| 2022-12-31 | 5816.67% |
| 2022-09-30 | -4024.29% |
| 2022-06-30 | -4188.22% |
| 2022-03-31 | -2524.60% |
| 2021-12-31 | -184.12% |
| 2021-09-30 | -153.08% |
| 2021-06-30 | -148.42% |
| 2021-03-31 | -142.25% |
| 2020-12-31 | -148.73% |
| 2020-09-30 | -123.84% |
| 2020-06-30 | -411.43% |
| 2020-03-31 | -407.43% |
| 2019-12-31 | -272.80% |
| 2019-09-30 | -113.46% |
| 2019-06-30 | -683.05% |
| 2019-03-31 | -962.79% |
| 2018-12-31 | -747.13% |
| 2018-09-30 | -987.12% |
| 2018-06-30 | -875.80% |
| 2018-03-31 | -653.44% |
| 2017-12-31 | -524.33% |
| 2017-09-30 | -334.52% |
| 2017-06-30 | -465.28% |
| 2017-03-31 | -532.85% |
| 2016-12-31 | -510.15% |
| 2016-09-30 | -453.20% |
| 2016-06-30 | -481.17% |
| 2016-03-31 | -425.02% |
| 2015-12-31 | -310.69% |
| 2015-09-30 | -375.45% |
| 2015-06-30 | -561.92% |
| 2015-03-31 | -467.24% |
| 2014-12-31 | -382.90% |
| 2014-09-30 | -426.04% |
| 2014-06-30 | -290.87% |
| 2014-03-31 | -315.76% |
| 2013-12-31 | -279.59% |
| 2013-09-30 | -313.97% |
| 2013-06-30 | -269.42% |
| 2013-03-31 | -321.04% |
| 2012-12-31 | -433.86% |
| 2012-09-30 | -375.87% |
| 2012-06-30 | -483.43% |
| 2012-03-31 | -395.38% |
| 2011-12-31 | -249.73% |
| 2011-09-30 | -265.12% |
| 2011-06-30 | -204.03% |
| 2011-03-31 | -155.96% |
| 2010-12-31 | -531.57% |
| 2009-12-31 | -5483.03% |
| 2007-09-30 | -6.06% |
| 2007-06-30 | -3.06% |
| 2007-03-31 | -2.54% |
| 2006-12-31 | 51.45% |
| 2006-09-30 | 65.45% |
| 2006-06-30 | 53.76% |
| 2006-03-31 | 37.71% |
| 2005-12-31 | 42.87% |
| 2005-09-30 | 63.34% |
| 2005-06-30 | 11.26% |
| 2005-03-31 | 48.61% |
| 2004-12-31 | 56.36% |
| 2004-09-30 | 40.51% |
| 2004-06-30 | 24.15% |
| 2004-03-31 | 34.09% |
| 2003-12-31 | 30.65% |
| 2003-09-30 | 59.84% |
| 2003-06-30 | 20.03% |
| 2003-03-31 | 31.28% |
| 2002-12-31 | 45.38% |
| 2002-09-30 | 42.08% |
